ICD-10 Coding for Bicytopenia(D61.1, D61.1B, D61.1D)
Learn about the ICD-10 coding for bicytopenia, including documentation requirements and common pitfalls. Ensure accurate billing and compliance.
Complete code families applicable to Bicytopenia
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| D61.1 | Drug-induced aplastic anemia with bicytopenia | Use when bicytopenia is due to drug-induced aplastic anemia. |
|
| D61.818 | Other pancytopenia | Use when bicytopenia is idiopathic or non-drug-induced. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutBicytopenia
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Bicytopenia.
Failing to document drug cause for bicytopenia
Impact
Clinical: Leads to mismanagement of underlying cause., Regulatory: Increases risk of non-compliance with coding standards., Financial: Potential for reduced reimbursement.
Mitigation
Always document drug name and dosage., Link cytopenia onset to drug administration.
Using D64.9 for bicytopenia without specifying cause
Impact
Reimbursement: May lead to lower reimbursement rates., Compliance: Increases risk of audit due to unspecified coding., Data Quality: Reduces accuracy of clinical data.
Mitigation
Use specific codes like D61.1 or D61.818 based on etiology.
Unspecified cytopenia coding
Impact
Using unspecified codes increases audit risk.
Mitigation
Document specific cell lines and causes.